Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Department of Oncology, Uppsala University Hospital, Uppsala, Sweden.
JNCI Cancer Spectr. 2023 Jul 3;7(4). doi: 10.1093/jncics/pkad050.
Current evidence on de novo metastatic breast cancer is based on data from women. This Swedish population-based cohort study compared the incidence over time and prognosis of de novo metastatic breast cancer between sexes using data from the Swedish National Quality Register for Breast Cancer. Joinpoint regression analysis was used to compare incidence trends in all stages (104 733 women, 648 men) and multivariate Cox regression analysis to investigate potential sex disparities in de novo metastatic breast cancer prognosis (6005 women, 41 men). For both sexes, increased trends were evident for cancer stages I and II, with a stabilizing trend at the later years for women, while stage III incidence remained stable. An increased trend for de novo metastatic breast cancer in women, and to a lesser extent in men, was observed. No difference in de novo metastatic breast cancer overall survival between sexes was observed (hazard ratio = 1.24; 95% confidence interval = 0.85 to 1.81). The comparable features in terms of incidence and prognosis of de novo metastatic breast cancer between sexes imply similarities, supporting the adoption of common treatment strategies.
目前关于新发转移性乳腺癌的证据基于来自女性的数据。这项基于瑞典人群的队列研究使用瑞典国家乳腺癌质量登记处的数据，比较了不同性别新发转移性乳腺癌的随时间变化的发生率和预后。使用 Joinpoint 回归分析比较了所有分期（104733 名女性，648 名男性）的发病趋势，并使用多变量 Cox 回归分析研究了新发转移性乳腺癌预后方面的潜在性别差异（6005 名女性，41 名男性）。对于两性，I 期和 II 期癌症的发病趋势明显增加，而女性在后期趋于稳定，而 III 期的发病率则保持稳定。观察到女性新发转移性乳腺癌的发病趋势增加，男性则略有增加。在新发转移性乳腺癌的总体生存率方面，两性之间无差异（危险比=1.24；95%置信区间=0.85 至 1.81）。两性新发转移性乳腺癌在发病和预后方面具有相似特征，这意味着存在相似性，支持采用共同的治疗策略。
